Incyclix Bio LLC, based in RTP, has recently announced the successful acquisition of an $11.25 million extension to its Series B financing. This additional funding is earmarked to facilitate the progression of the first-in-human clinical trial of INX-315, an oral inhibitor targeting cyclin-dependent kinase 2 (CDK2) designed to combat advanced and treatment-resistant cancers.
The recent investors in the Series B extension include notable names such as Eshelman Ventures, Eli Lilly and Company, Pharmacosmos, along with a fresh addition, Cape Fear BioCapital. This financial influx signifies a robust validation of the exceptional potential of INX-315, which Incyclix Bio is developing to cater to the unmet needs of patients grappling with advanced, treatment-resistant breast and ovarian cancers.
Patrick Roberts, Pharm.D., Ph.D., the chief executive officer and co-founder of Incyclix Bio, expressed gratitude for the unwavering support received, emphasizing that the additional capital injection positions the company to conclude this critical study successfully. This achievement will mark significant milestones in the journey towards providing precision treatments to patients in dire need.
While CDK2 is a well-known instigator of uncontrolled cell proliferation in certain cancer types, developing efficacious drugs to counter this kinase has posed significant challenges. Leveraging their profound comprehension of the critical structural aspects within CDK2’s drug-binding site, Incyclix Bio has devised a potent and selective CDK2 inhibitor in the form of INX-315.
Fred Eshelman, co-founder and chairman of the board at Eshelman Ventures LLC, acknowledged the promise that INX-315 holds as a viable treatment modality for patients with resistant forms of breast and ovarian cancer. The enduring support from investors reflects their confidence in Incyclix’s adept and dynamic team as they navigate the path towards bringing this promising therapy to fruition.
The INX-315-01 study represents a pivotal first-in-human Phase 1/2 trial that is open-label and aims to evaluate the efficacy of INX-315 in patients grappling with advanced or metastatic cancers. These encompass CDK4/6 inhibitor-resistant estrogen receptor-positive/human epidermal growth factor receptor 2 negative (ER+/HER2) breast cancer or CCNE1-amplified solid tumors. The study design incorporates dose-escalation and dose-expansion strategies to meticulously assess safety, pharmacokinetics, and initial antitumor activity.
In a significant development, the company presented interim clinical data from the dose escalation phase of the study at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. According to the initial results, the CDK inhibitor demonstrated favorable safety profiles and tolerability, coupled with encouraging signs of potential antitumor efficacy in heavily pretreated patients diagnosed with advanced, treatment-resistant breast and ovarian cancers. The study remains on track for completion in mid-2026.
Patrick Roberts highlighted the conducive environment of RTP, attributing the company’s growth and successful attraction of robust investors to the supportive life science ecosystem in the region. Incyclix Bio takes pride in being an integral part of this vibrant community dedicated to fostering innovation and paving the way for enhanced patient outcomes.
Moreover, the collaboration between two of the world’s largest life sciences entities has expanded to amplify the production of advanced medications in North Carolina. Restore3d, a Durham-based manufacturer specializing in three-dimensional printed orthopedic implants, recently concluded a new investment round valued at $104 million, with a substantial portion of $65 million originating from a global private equity firm and the remaining $39 million sourced from existing shareholders.
In a groundbreaking move, biotechnology trailblazer Genentech initiated the construction of a $700 million manufacturing facility in Holly Springs. This milestone marks Genentech’s inaugural production site on the East Coast and signifies a momentous expansion of North Carolina’s life sciences landscape.
Key Takeaways:
– Incyclix Bio has secured $11.25 million to advance the first-in-human clinical trial of INX-315 targeting hard-to-treat cancers.
– The funding round includes prominent investors such as Eshelman Ventures, Eli Lilly and Company, Pharmacosmos, and Cape Fear BioCapital.
– INX-315 shows promise in addressing treatment-resistant breast and ovarian cancers, with encouraging interim clinical data supporting its safety and potential efficacy.
– The INX-315-01 study is progressing well, with completion expected by mid-2026, showcasing the commitment of Incyclix Bio to deliver precision treatments to patients.
– The thriving life sciences ecosystem in North Carolina continues to attract significant investments and partnerships, fueling innovation and growth in the sector.
Read more on ncbiotech.org